2026-04-17T02:59:45Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4738362025-09-13T09:14:12Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Waryah, Charlene author Cursons, Joseph author Foroutan, Momeneh author Pflueger, Christian author Wang, Edina author Molania, Ramyar author Woodward, Eleanor author Sorolla, Anabel author Wallis, Christopher author Moses, Colette author Glas, Irina author Magalhães, Leandro author Thompson, Erik W. author Fearnley, Liam G. author Chaffer, Christine L. author Davis, Melissa author Papenfuss, Anthony T. author Redfern, Andrew author Lister, Ryan author Esteller, M author Blancafort, Pilar author 2023 Altres ajuts: National Health and Medical Research Council (NHMRC) grant APP1147528; NHMRC grants APP1165208 and APP1187328; National Breast Cancer Foundation IIRS-22-044; Cancer Council New South Wales APP2013068; Cancer Council Western Australia APP2004608 Epithelial-mesenchymal transition (EMT) is a reversible transcriptional program invoked by cancer cells to drive cancer progression. Transcription factor ZEB1 is a master regulator of EMT, driving disease recurrence in poor-outcome triple negative breast cancers (TNBCs). Here, this work silences ZEB1 in TNBC models by CRISPR/dCas9-mediated epigenetic editing, resulting in highly-specific and nearly complete suppression of ZEB1 in vivo, accompanied by long-lasting tumor inhibition. Integrated "omic" changes promoted by dCas9 linked to the KRAB domain (dCas9-KRAB) enabled the discovery of a ZEB1-dependent-signature of 26 genes differentially-expressed and -methylated, including the reactivation and enhanced chromatin accessibility in cell adhesion loci, outlining epigenetic reprogramming toward a more epithelial state. In the ZEB1 locus transcriptional silencing is associated with induction of locally-spread heterochromatin, significant changes in DNA methylation at specific CpGs, gain of H3K9me3, and a near complete erasure of H3K4me3 in the ZEB1 promoter. Epigenetic shifts induced by ZEB1-silencing are enriched in a subset of human breast tumors, illuminating a clinically-relevant hybrid-like state. Thus, the synthetic epi-silencing of ZEB1 induces stable "lock-in" epigenetic reprogramming of mesenchymal tumors associated with a distinct and stable epigenetic landscape. This work outlines epigenome-engineering approaches for reversing EMT and customizable precision molecular oncology approaches for targeting poor outcome breast cancers. Cancer epigenetics CRISPR/dCas9 repression Epithelial-mesenchymaltransition Triple negative breast cancer ZEB1 Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer